share_log

22nd Century Group to Participate in the Emerging Growth Virtual Conference on August 21, 2024

22nd Century Group to Participate in the Emerging Growth Virtual Conference on August 21, 2024

22世紀集團將於2024年8月21日參加新興成長虛擬會議。
newsfile ·  08/20 17:52

Mocksville, North Carolina--(Newsfile Corp. - August 20, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, today announced that it will provide a brief corporate update as part of the Emerging Growth Virtual Conference on Wednesday, August 21, 2024 at 4:25 PM Eastern Time.

北卡羅來納州莫克斯維爾——(Newsfile Corp.——2024年8月20日)——22世紀集團公司(NASDAQ: XXII),一家專注於尼古丁危害減少和合同製造的菸草產品公司,今天宣佈將在2024年8月21日星期三下午4:25美國東部時間作爲新興增長虛擬會議的一部分提供簡要的企業更新。

To access the live presentation, please use the events link online at .

要獲取實時演示,請使用在線事件鏈接。

About 22nd Century Group, Inc.
22nd Century Group, Inc. (NASDAQ: XXII) is an agricultural biotechnology company focused on tobacco harm reduction by offering tobacco products with 95% less nicotine, designed to improve health and wellness by helping smokers smoke less. Backed by comprehensive and extensively patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, the Company has pioneered the development of high-yield, proprietary reduced nicotine content (RNC) tobacco plants and clinically validated RNC cigarette products. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021. The Company is a subsequent participating manufacturer under the Master Settlement Agreement ("MSA") and vertically integrated for the production of both its own products and contract manufacturing operations ("CMO"), which consist primarily of branded filtered cigars and conventional cigarettes.

關於22世紀集團公司
22世紀集團公司(NASDAQ: XXII)是一家農業生物技術公司,專注於通過提供含有95%少尼古丁的菸草產品,幫助吸菸者減少菸草危害,旨在通過幫助吸菸者減少吸菸來改善健康和福祉。公司擁有全面和廣泛獲得專利的技術來調節菸草植物中尼古丁生物合成活動,開創了高產量、專有的降低尼古丁含量(RNC)菸草植物和經臨床驗證的RNC香菸產品的發展。公司於2021年12月獲得了首個、也是唯一一個可燃菸草風險改善菸草製品(MRTP)授權的FDA授權。公司是《和解協議》(「MSA」)下的後續參與制造商,並垂直整合了自己的產品和合同製造運營(「CMO」),主要包括品牌濾嘴雪茄和傳統香菸的生產。

Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.

欲了解更多,請訪問 xxiicentury.com,在Twitter、領英和YouTube上了解我們公司的最新動態。

Learn more about VLN at tryvln.com.

了解有關VLN的更多信息,請訪問 tryvln.com。

Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
mkreps@xxiicentury.com
214-597-8200

投資者關係與媒體聯繫
Matt Kreps
投資者關係
22世紀集團
mkreps@xxiicentury.com
214-597-8200

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論